tiprankstipranks
Cara Therapeutics (CARA)
NASDAQ:CARA
US Market

Cara Therapeutics (CARA) Income Statement

Compare
2,283 Followers

Cara Therapeutics Income Statement

Last quarter (Q3 2024), Cara Therapeutics's total revenue was $2.56M, a decrease of -47.47% from the same quarter last year. In Q3, Cara Therapeutics's net income was $-12.48M. See Cara Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 20.97M$ 41.87M$ 23.03M$ 135.08M$ 19.89M
Gross Profit
$ 14.79M$ 34.60M$ 21.47M$ 28.01M$ -93.28M
Operating Expenses
$ 136.29M$ 122.14M$ 112.11M$ 129.70M$ 131.56M
Depreciation and Amortization
$ 259.00K$ 1.67M$ 1.55M$ 1.01M$ 799.00K
EBITDA
$ -117.65M$ -83.80M$ -88.19M$ 5.59M$ -111.48M
Operating Income
$ -121.50M$ -87.53M$ -89.08M$ 5.38M$ -111.68M
Other Income/Expenses
$ 2.98M$ 2.06M$ 642.00K$ 2.33M$ 4.49M
Pretax Income
$ -118.51M$ -85.47M$ -88.44M$ 7.72M$ -107.19M
Net Income
$ -118.51M$ -83.41M$ -88.19M$ 8.41M$ -106.37M
Per Share Metrics
Basic EPS
$ -2.19$ -1.55$ -1.74$ 0.18$ -2.49
Diluted EPS
$ -2.19$ -1.55$ -1.74$ 0.18$ -2.49
Weighted Average Shares Outstanding
54.15M 53.65M 50.72M 47.41M 42.67M
Weighted Average Shares Outstanding (Diluted)
54.15M 53.65M 50.72M 47.92M 42.67M
Currency in USD

Cara Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis